Effector Therapeutics Correlations
| EFTRDelisted Stock | USD 0.13 0.03 30.00% |
The current 90-days correlation between Effector Therapeutics and Indaptus Therapeutics is -0.05 (i.e., Good diversification). The correlation of Effector Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Effector Therapeutics Correlation With Market
Significant diversification
The correlation between Effector Therapeutics and DJI is 0.03 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Effector Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Effector |
Moving together with Effector Stock
| 0.68 | DWTX | DWTX Symbol Change | PairCorr |
Moving against Effector Stock
| 0.46 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.42 | VCYT | Veracyte | PairCorr |
| 0.39 | VERA | Vera Therapeutics | PairCorr |
| 0.38 | DNLI | Denali Therapeutics | PairCorr |
| 0.38 | DSGN | Design Therapeutics Trending | PairCorr |
| 0.49 | VKTX | Viking Therapeutics Earnings Call This Week | PairCorr |
| 0.39 | VRNA | Verona Pharma PLC | PairCorr |
| 0.36 | VRDN | Viridian Therapeutics | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Risk-Adjusted Indicators
There is a big difference between Effector Stock performing well and Effector Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Effector Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| INDP | 3.51 | (0.52) | 0.00 | (0.16) | 0.00 | 8.39 | 27.48 | |||
| JSPR | 3.47 | (0.14) | (0.01) | 0.01 | 5.04 | 9.08 | 28.74 | |||
| RNXT | 3.33 | (0.28) | 0.00 | (0.49) | 0.00 | 5.61 | 40.06 | |||
| ENSC | 4.82 | (1.11) | 0.00 | (5.79) | 0.00 | 6.06 | 80.38 | |||
| VRPX | 6.12 | (0.93) | 0.00 | (0.55) | 0.00 | 10.96 | 57.08 |
Effector Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Effector Therapeutics stock to make a market-neutral strategy. Peer analysis of Effector Therapeutics could also be used in its relative valuation, which is a method of valuing Effector Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Effector Therapeutics Corporate Management
| Siegfried Reich | CoFounder Board | Profile | |
| Mayank MD | Chief Officer | Profile | |
| Michael MBA | Chief Officer | Profile | |
| Davide Ruggero | CoFounder Board | Profile | |
| Douglas MD | Chief Officer | Profile | |
| Kevan Shokat | CoFounder Board | Profile |
Still Interested in Effector Therapeutics?
Investing in delisted delisted stocks can be risky, as the stock is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.